On the public citation graph

Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis

https://doi.org/10.1176/appi.ajp.2016.15081035
0 signed · 309 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archpsyc.1989.01810100064012openalex-snapshot
Antidepressants in 'Depressed' Schizophrenic Inpatients
inferredcites →https://doi.org/10.1001/jamapsychiatry.2014.112openalex-snapshot
Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders
inferredcites →https://doi.org/10.1002/9780470712184openalex-snapshot
Cochrane Handbook for Systematic Reviews of Interventions
inferredcites →https://doi.org/10.1007/978-3-642-54769-0openalex-snapshot
Kompendium der Psychiatrischen Pharmakotherapie
inferredcites →https://doi.org/10.1007/s00406-013-0406-3openalex-snapshot
Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.1016/0197-2456(86)90046-2openalex-snapshot
Meta-analysis in clinical trials
inferredcites →https://doi.org/10.1016/j.eurpsy.2014.01.007openalex-snapshot
Impact of primary negative symptoms on functional outcomes in schizophrenia
inferredcites →https://doi.org/10.1016/j.jad.2015.03.021openalex-snapshot
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials
inferredcites →https://doi.org/10.1016/j.jclinepi.2004.02.018openalex-snapshot
Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time
inferredcites →https://doi.org/10.1016/j.jclinepi.2005.06.006openalex-snapshot
Imputing missing standard deviations in meta-analyses can provide accurate results
inferredcites →https://doi.org/10.1016/j.jclinepi.2008.03.004openalex-snapshot
Attention should be given to multiplicity issues in systematic reviews
inferredcites →https://doi.org/10.1016/j.jclinepi.2009.06.005openalex-snapshot
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
inferredcites →https://doi.org/10.1016/j.schres.2006.03.034openalex-snapshot
Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome
inferredcites →https://doi.org/10.1016/j.schres.2006.09.027openalex-snapshot
The burden of depressive symptoms in the long-term treatment of patients with schizophrenia
inferredcites →https://doi.org/10.1016/j.schres.2011.11.030openalex-snapshot
Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis
inferredcites →https://doi.org/10.1016/j.schres.2014.08.015openalex-snapshot
Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s0140-6736(09)60995-8openalex-snapshot
Schizophrenia
inferredcites →https://doi.org/10.1016/s0893-133x(99)00122-0openalex-snapshot
Assessing the Efficacy of Treatments for the Deficit Syndrome of Schizophrenia
inferredcites →https://doi.org/10.1017/s0033291703007645openalex-snapshot
Antidepressants for the treatment of depression in people with schizophrenia: a systematic review
inferredcites →https://doi.org/10.1017/s1461145713000667openalex-snapshot
Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia
inferredcites →https://doi.org/10.1053/comp.2001.24577openalex-snapshot
Depression in patients with schizophrenia during an acute psychotic episode
inferredcites →https://doi.org/10.1056/nejmsa065779openalex-snapshot
Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
inferredcites →https://doi.org/10.1080/08039480801959307openalex-snapshot
Negative symptoms in schizophrenia—A review
inferredcites →https://doi.org/10.1093/ijnp/pyv049openalex-snapshot
Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia
inferredcites →https://doi.org/10.1093/oxfordhb/9780199797004.013.011openalex-snapshot
Schizophrenia
inferredcites →https://doi.org/10.1093/oxfordjournals.schbul.a033362openalex-snapshot
Depression During the Longitudinal Course of Schizophrenia
inferredcites →https://doi.org/10.1093/schbul/13.2.261openalex-snapshot
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
inferredcites →https://doi.org/10.1093/schbul/sbj053openalex-snapshot
The NIMH-MATRICS Consensus Statement on Negative Symptoms
inferredcites →https://doi.org/10.1093/schbul/sbl071openalex-snapshot
Psychiatric Symptoms and Quality of Life in Schizophrenia: A Meta-Analysis
inferredcites →https://doi.org/10.1093/schbul/sbn135openalex-snapshot
Psychiatric Comorbidities and Schizophrenia
inferredcites →https://doi.org/10.1093/schbul/sbp116openalex-snapshot
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
inferredcites →https://doi.org/10.1093/schbul/sbt158openalex-snapshot
Progress in the Study of Negative Symptoms
inferredcites →https://doi.org/10.1093/schbul/sbu170openalex-snapshot
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials
inferredcites →https://doi.org/10.1111/j.0006-341x.2000.00455.xopenalex-snapshot
Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis
inferredcites →https://doi.org/10.1136/bmj.315.7109.629openalex-snapshot
Bias in meta-analysis detected by a simple, graphical test
inferredcites →https://doi.org/10.1136/bmj.317.7167.1181openalex-snapshot
Content and quality of 2000 controlled trials in schizophrenia over 50 years
inferredcites →https://doi.org/10.1136/bmj.327.7414.557openalex-snapshot
Measuring inconsistency in meta-analyses
inferredcites →https://doi.org/10.1136/bmj.38356.424606.8fopenalex-snapshot
Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors
inferredcites →https://doi.org/10.1136/bmj.39489.470347.adopenalex-snapshot
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
inferredcites →https://doi.org/10.1136/bmj.39493.646875.aeopenalex-snapshot
Going from evidence to recommendations
inferredcites →https://doi.org/10.1136/jnnp.23.1.56openalex-snapshot
A RATING SCALE FOR DEPRESSION
inferredcites →https://doi.org/10.1176/ajp.145.5.578openalex-snapshot
Deficit and nondeficit forms of schizophrenia: the concept
inferredcites →https://doi.org/10.1176/appi.ajp.157.9.1379openalex-snapshot
Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents
inferredcites →https://doi.org/10.1176/appi.ajp.161.1.1openalex-snapshot
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
inferredcites →https://doi.org/10.1176/appi.ajp.161.9.1692openalex-snapshot
Safety Reporting in Randomized Trials of Mental Health Interventions
inferredcites →https://doi.org/10.1176/appi.ajp.162.10.1957openalex-snapshot
Industry Sponsorship and Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry
inferredcites →https://doi.org/10.1176/appi.ajp.2009.09060802openalex-snapshot
International Consensus Study of Antipsychotic Dosing
inferredcites →https://doi.org/10.1176/appi.ajp.2012.12010109openalex-snapshot
The Clinical Assessment Interview for Negative Symptoms (CAINS): Final Development and Validation
inferredcites →https://doi.org/10.1177/0269881110391123openalex-snapshot
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
inferredcites →https://doi.org/10.1186/1744-859x-12-32openalex-snapshot
Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review
inferredcites →https://doi.org/10.1186/1745-6215-9-22openalex-snapshot
An assessment of the quality of randomised controlled trials conducted in China
inferredcites →https://doi.org/10.1186/s12916-015-0317-4openalex-snapshot
Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination
inferredcites →https://doi.org/10.1192/apt.bp.108.005629openalex-snapshot
Depression in schizophrenia and early psychosis: implications for assessment and treatment
inferredcites →https://doi.org/10.1192/bjp.134.4.382openalex-snapshot
A New Depression Scale Designed to be Sensitive to Change
inferredcites →https://doi.org/10.1192/bjp.187.1.9openalex-snapshot
Schizophrenia and suicide: Systematic review of risk factors
inferredcites →https://doi.org/10.1192/bjp.bp.109.067710openalex-snapshot
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis
inferredcites →https://doi.org/10.1192/s0007125000291502openalex-snapshot
Scale for the Assessment of Negative Symptoms (SANS)*
inferredcites →https://doi.org/10.1192/s0007125000292581openalex-snapshot
Assessing Depression in Schizophrenia: The Calgary Depression Scale
inferredcites →https://doi.org/10.1371/journal.pone.0019070openalex-snapshot
How to Obtain NNT from Cohen's d: Comparison of Two Methods
inferredcites →https://doi.org/10.2307/1270020openalex-snapshot
Statistical Power Analysis for the Behavioral Sciences
inferredcites →https://doi.org/10.2466/pr0.1962.10.3.799openalex-snapshot
The Brief Psychiatric Rating Scale
inferredcites →https://doi.org/10.3371/csrp.1.4.4openalex-snapshot
Drug Treatment of Depressive Symptoms in Schizophrenia
inferredcites →https://doi.org/10.4088/jcp.08m04250yelopenalex-snapshot
Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice
inferredcites →https://doi.org/10.4088/jcp.v68n0417openalex-snapshot
Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.5085569openalex-extracted
Effect-Size Deflation with Increasing Sample-Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2018.4489openalex-snapshot
Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2024.2652openalex-snapshot
Prioritization of Psychopathological Symptoms and Clinical Characterization in Psychiatric Diagnoses
inferred← citeshttps://doi.org/10.1002/9781119870203.mpg001.pub2openalex-snapshot
Schizophrenia and Related Psychoses
inferred← citeshttps://doi.org/10.1002/brb3.1600openalex-snapshot
Adjunct ketamine treatment of depression in treatment‐resistant schizophrenia patients is unsatisfactory in pilot and secondary follow‐up studies
inferred← citeshttps://doi.org/10.1002/brb3.1991openalex-snapshot
Brain imaging features in schizophrenia with co‐occurring auditory verbal hallucinations and depressive symptoms—Implication for novel therapeutic strategies to alleviate the reciprocal deterioration
inferred← citeshttps://doi.org/10.1002/gps3.70045openalex-snapshot
Agomelatine as augmentation therapy with second‐generation antipsychotics for negative symptoms of schizophrenia: An open‐label randomised clinical trial and electroencephalogram‐derived model for treatment response prediction
inferred← citeshttps://doi.org/10.1002/hup.2571openalex-snapshot
Adjunctive antidepressant use in schizophrenia in China: A national survey (2002–2012)
inferred← citeshttps://doi.org/10.1002/npr2.12308openalex-snapshot
A case of postpsychotic depression improved by switching antipsychotic monotherapy
inferred← citeshttps://doi.org/10.1002/prp2.1065openalex-snapshot
Lower sertraline plasma concentration in patients co‐medicated with clozapine—Implications for pharmacological augmentation strategies in schizophrenia
inferred← citeshttps://doi.org/10.1002/wps.70066openalex-snapshot
Real‐world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages
inferred← citeshttps://doi.org/10.1007/978-3-030-29450-2_19openalex-snapshot
Adjunctive Medications
inferred← citeshttps://doi.org/10.1007/978-3-030-35206-6_17openalex-snapshot
Predicting Outcome in Schizophrenia: Neuroimaging and Clinical Assessments
inferred← citeshttps://doi.org/10.1007/978-3-030-62059-2_392openalex-snapshot
Evidence-Based Treatment with Antipsychotics in Schizophrenia: S3-Guideline and Current References
inferred← citeshttps://doi.org/10.1007/978-3-030-85493-5_2116-1openalex-snapshot
Sexual Jealousy: Othello Syndrome
inferred← citeshttps://doi.org/10.1007/978-3-032-06209-3_6openalex-snapshot
Negative Symptoms in Schizophrenia: The Role of Pharmacotherapy
inferred← citeshttps://doi.org/10.1007/978-3-319-56015-1_392-1openalex-snapshot
Evidence-Based Treatment with Antipsychotics in Schizophrenia: S3-Guideline and Current References
inferred← citeshttps://doi.org/10.1007/978-3-319-97202-2openalex-snapshot
Delusions in Context
inferred← citeshttps://doi.org/10.1007/978-3-319-97202-2_1openalex-snapshot
Delusional Beliefs in the Clinical Context
inferred← citeshttps://doi.org/10.1007/978-3-642-45028-0_31-2openalex-snapshot
Psychopharmakotherapie – klinisch-empirische Grundlagen
inferred← citeshttps://doi.org/10.1007/978-3-662-57334-1_3openalex-snapshot
Antipsychotika
inferred← citeshttps://doi.org/10.1007/978-3-662-59380-6_5openalex-snapshot
Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a)
inferred← citeshttps://doi.org/10.1007/978-3-662-59380-6_7openalex-snapshot
Behandlung unter besonderen Bedingungen (Modul 4c)
inferred← citeshttps://doi.org/10.1007/s00115-022-01332-zopenalex-snapshot
Zwangssymptome bei psychotischen Störungen: Pathogenese und Therapie
inferred← citeshttps://doi.org/10.1007/s00213-018-5133-zopenalex-snapshot
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis
inferred← citeshttps://doi.org/10.1007/s00228-020-02830-2openalex-snapshot
Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia
inferred← citeshttps://doi.org/10.1007/s00228-020-02973-2openalex-snapshot
Add-on pharmacotherapy for patients with first-episode schizophrenia: a clinical perspective
inferred← citeshttps://doi.org/10.1007/s00406-018-0869-3openalex-snapshot
Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00406-025-02045-5openalex-snapshot
Enhancing mental health care: a problem, resources and goals oriented multidimensional framework (PRoGO)
inferred← citeshttps://doi.org/10.1007/s00406-025-02160-3openalex-snapshot
Low-dose paliperidone combined with sertraline for first-episode and medication-naïve patients with schizophrenia: an open-label, randomized trial
inferred← citeshttps://doi.org/10.1007/s00406-026-02229-7openalex-snapshot
Efficacy of sertraline combined with low-dose antipsychotics in first-episode schizophrenia
inferred← citeshttps://doi.org/10.1007/s00521-020-05408-2openalex-snapshot
Beyond traditional approaches: a partial directed coherence with graph theory-based mental load assessment using EEG modality
inferred← citeshttps://doi.org/10.1007/s00737-017-0748-3openalex-snapshot
Case study of first episode schizophrenia in pregnancy and postpartum
inferred← citeshttps://doi.org/10.1007/s12264-021-00740-6openalex-snapshot
Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia
inferred← citeshttps://doi.org/10.1007/s15005-017-2015-6openalex-snapshot
Depressive Stimmungslage und Negativsymptome werden verbessert
inferred← citeshttps://doi.org/10.1007/s15005-017-2413-9openalex-snapshot
Schizophrenie — eine Angststörung? Aktuelle Hinweise für eine neue Sichtweise
inferred← citeshttps://doi.org/10.1007/s15005-017-2421-9openalex-snapshot
Wirksamkeit von antipsychotischer Kombinationstherapie bei Schizophrenie
inferred← citeshttps://doi.org/10.1007/s15005-018-2370-yopenalex-snapshot
Medikamentöse Behandlungsresistenz bei der Schizophrenie
inferred← citeshttps://doi.org/10.1007/s15005-023-3385-6openalex-snapshot
Chancen durch Off-Label-Therapie
inferred← citeshttps://doi.org/10.1007/s15202-016-1523-4openalex-snapshot
Mit Antidepressiva auch gegen die Negativsymptomatik
inferred← citeshttps://doi.org/10.1007/s40261-024-01377-9openalex-snapshot
Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment
inferred← citeshttps://doi.org/10.1007/s40263-017-0428-xopenalex-snapshot
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
inferred← citeshttps://doi.org/10.1007/s40263-024-01151-7openalex-snapshot
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
inferred← citeshttps://doi.org/10.1007/s40265-017-0789-yopenalex-snapshot
Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review
inferred← citeshttps://doi.org/10.1007/s44192-025-00283-6openalex-snapshot
Strategic and tactic use of antipsychotic medications in schizophrenia: a perspective on current prescription practice
inferred← citeshttps://doi.org/10.1016/b978-0-323-58131-8.00007-0openalex-snapshot
Psychiatric Comorbidity in Major Depressive Disorder
inferred← citeshttps://doi.org/10.1016/b978-0-443-18496-3.00010-0openalex-snapshot
Convulsive therapy for psychiatric disorders
inferred← citeshttps://doi.org/10.1016/b978-3-437-21224-6.00055-4openalex-snapshot
Literaturverzeichnis zu Voderholzer (Hrsg.): Therapie psychischer Erkrankungen, 20. Auflage
inferred← citeshttps://doi.org/10.1016/b978-3-437-22485-0.00010-5openalex-snapshot
Schizophrenien und andere psychotische Störungen
inferred← citeshttps://doi.org/10.1016/b978-3-437-22487-4.16001-0openalex-snapshot
Grundlagen der Diagnostik und Therapie
inferred← citeshttps://doi.org/10.1016/b978-3-437-22541-3.00015-4openalex-snapshot
Therapie für spezifische Problemkonstellationen
inferred← citeshttps://doi.org/10.1016/b978-3-437-23491-0.00005-1openalex-snapshot
Schizophrenien und andere psychotische Störungen
inferred← citeshttps://doi.org/10.1016/b978-3-437-23492-7.00005-7openalex-snapshot
Schizophrenien und andere psychotische Störungen, Katatonie
inferred← citeshttps://doi.org/10.1016/b978-3-437-24911-2.16001-8openalex-snapshot
Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage
inferred← citeshttps://doi.org/10.1016/j.ajp.2019.08.010openalex-snapshot
Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: Findings of the 2016 Research on Asian Psychotropic Prescription Patterns (REAP) survey
inferred← citeshttps://doi.org/10.1016/j.ajp.2021.102742openalex-snapshot
Patterns of antipsychotic prescriptions in patients with schizophrenia in China: A national survey
inferred← citeshttps://doi.org/10.1016/j.ajp.2022.103375openalex-snapshot
Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment
inferred← citeshttps://doi.org/10.1016/j.bbr.2020.112628openalex-snapshot
Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?
inferred← citeshttps://doi.org/10.1016/j.brat.2020.103734openalex-snapshot
Positive Memory Training for the Treatment of Depression in Schizophrenia: A Randomised Controlled Trial
inferred← citeshttps://doi.org/10.1016/j.ceca.2025.103054openalex-snapshot
Calcium imaging: Unraveling the neurobiological mechanisms of depression across cellular and circuit dimensions
inferred← citeshttps://doi.org/10.1016/j.chc.2016.12.014openalex-snapshot
Schizophrenia and Psychosis
inferred← citeshttps://doi.org/10.1016/j.comppsych.2018.12.004openalex-snapshot
The association between comorbid psychiatric diagnoses and hospitalization-related factors among individuals with schizophrenia
inferred← citeshttps://doi.org/10.1016/j.conctc.2020.100537openalex-snapshot
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial
inferred← citeshttps://doi.org/10.1016/j.eclinm.2024.102473openalex-snapshot
Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.eclinm.2025.103583openalex-snapshot
Non-invasive brain stimulation augmentation therapy for treatment-resistant schizophrenia: a systematic review and network meta-analysis
inferred← citeshttps://doi.org/10.1016/j.ejpsy.2025.100302openalex-snapshot
Genetic evidence of increased schizophrenia risk due to antidepressant use in European and East Asian populations
inferred← citeshttps://doi.org/10.1016/j.euroneuro.2017.11.007openalex-snapshot
Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
inferred← citeshttps://doi.org/10.1016/j.forsciint.2026.112976openalex-snapshot
Non-European migrants with schizophrenia spectrum disorders in Swiss forensic and general psychiatric care facilities – A comparative study using machine learning
inferred← citeshttps://doi.org/10.1016/j.genhosppsych.2019.11.002openalex-snapshot
Physical exercise for negative symptoms of schizophrenia: Systematic review of randomized controlled trials and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.genhosppsych.2021.04.010openalex-snapshot
Association of depressive symptoms with cognitive impairment in patients with never-treated first-episode schizophrenia: Analysis of the Depression in Schizophrenia in China (DISC) study
inferred← citeshttps://doi.org/10.1016/j.imr.2025.101224openalex-snapshot
Effectiveness of herbal medicine as an add-on to antipsychotics in patients with schizophrenia spectrum disorders accompanied by depression: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.isci.2023.106773openalex-snapshot
Major depression-related factor NEGR1 controls salivary secretion in mouse submandibular glands
inferred← citeshttps://doi.org/10.1016/j.jad.2016.08.068openalex-snapshot
The effect of comorbid depression on facial and prosody emotion recognition in first-episode schizophrenia spectrum
inferred← citeshttps://doi.org/10.1016/j.jad.2017.12.088openalex-snapshot
Co-morbid depressive disorder is associated with better neurocognitive performance in first episode schizophrenia spectrum
inferred← citeshttps://doi.org/10.1016/j.jad.2021.04.064openalex-snapshot
“Apples and pears are similar, but still different things.” Bipolar disorder and schizophrenia- discrete disorders or just dimensions ?
inferred← citeshttps://doi.org/10.1016/j.jad.2022.09.037openalex-snapshot
Electrical stimulus combined with venlafaxine and mirtazapine improves brain Ca2+ activity, pre-pulse inhibition, and immobility time in a model of major depressive disorder in schizophrenia
inferred← citeshttps://doi.org/10.1016/j.jad.2024.01.050openalex-snapshot
Improving depressive symptoms in patients with schizophrenia using bilateral bipolar-nonbalanced prefrontal tDCS: Results from a double-blind sham-controlled trial
inferred← citeshttps://doi.org/10.1016/j.jpsychires.2024.03.048openalex-snapshot
Efficacy and safety of low-dose amisulpride versus olanzapine-fluoxetine combination in post-schizophrenic depression: A randomized controlled trial
inferred← citeshttps://doi.org/10.1016/j.neubiorev.2020.06.004openalex-snapshot
Pathophysiology of negative symptom dimensions of schizophrenia – Current developments and implications for treatment
inferred← citeshttps://doi.org/10.1016/j.neulet.2020.135033openalex-snapshot
Depressive symptoms combined with auditory hallucinations are accompanied with severe gray matter brain impairments in patients with first-episode untreated schizophrenia – A pilot study in China
inferred← citeshttps://doi.org/10.1016/j.pnpbp.2022.110641openalex-snapshot
3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort
inferred← citeshttps://doi.org/10.1016/j.pnpbp.2026.111749openalex-snapshot
Advances in schizophrenia research and treatment: exploring neurotransmitter imbalances, genetics, and innovative therapies
inferred← citeshttps://doi.org/10.1016/j.psychres.2023.115104openalex-snapshot
Efficacy of 5-HT2A antagonists on negative symptoms in patients with schizophrenia: A meta-analysis
inferred← citeshttps://doi.org/10.1016/j.psychres.2024.116126openalex-snapshot
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
inferred← citeshttps://doi.org/10.1016/j.schres.2017.06.029openalex-snapshot
Prevalence, demographic and clinical features of comorbid depressive symptoms in drug naïve patients with schizophrenia presenting with first episode psychosis
inferred← citeshttps://doi.org/10.1016/j.schres.2018.09.006openalex-snapshot
A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone
inferred← citeshttps://doi.org/10.1016/j.schres.2018.10.022openalex-snapshot
Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence
inferred← citeshttps://doi.org/10.1016/j.schres.2018.12.007openalex-snapshot
Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
inferred← citeshttps://doi.org/10.1016/j.schres.2019.01.028openalex-snapshot
Citalopram in first episode schizophrenia: The DECIFER trial
inferred← citeshttps://doi.org/10.1016/j.schres.2019.07.030openalex-snapshot
Meditation-based mind-body therapies for negative symptoms of schizophrenia: Systematic review of randomized controlled trials and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.schres.2021.10.005openalex-snapshot
Intermittent theta burst stimulation of cerebellar vermis enhances fronto-cerebellar resting state functional connectivity in schizophrenia with predominant negative symptoms: A randomized controlled trial
inferred← citeshttps://doi.org/10.1016/j.schres.2021.11.048openalex-snapshot
The specific phenotype of depression in recent onset schizophrenia spectrum disorders: A symptom profile and network comparison to recent onset major depressive disorder without psychotic features
inferred← citeshttps://doi.org/10.1016/j.schres.2023.10.003openalex-snapshot
Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations
inferred← citeshttps://doi.org/10.1016/j.schres.2023.11.015openalex-snapshot
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
inferred← citeshttps://doi.org/10.1016/j.schres.2024.02.025openalex-snapshot
Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia
inferred← citeshttps://doi.org/10.1016/j.schres.2024.05.020openalex-snapshot
The effect of second-generation antipsychotics on anxiety/depression in patients with schizophrenia: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.schres.2026.03.003openalex-snapshot
Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review
inferred← citeshttps://doi.org/10.1016/j.schres.2026.04.027openalex-snapshot
A scoping review of targeted psychological interventions for negative symptoms in schizophrenia
inferred← citeshttps://doi.org/10.1016/j.schres.2026.05.012openalex-snapshot
Negative symptoms in the Hierarchical Taxonomy of Psychopathology: Nosology, etiology, and pathophysiology
inferred← citeshttps://doi.org/10.1016/s0140-6736(17)30181-2openalex-snapshot
Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry
inferred← citeshttps://doi.org/10.1016/s2215-0366(25)00031-8openalex-snapshot
INTEGRATE: international guidelines for the algorithmic treatment of schizophrenia
inferred← citeshttps://doi.org/10.1016/s2215-0366(26)00174-4openalex-snapshot
Temporal course of symptom domain improvement in schizophrenia: individual participant data analysis of six antipsychotic drug trials
inferred← citeshttps://doi.org/10.1017/9781108539593.012openalex-snapshot
Depression in Older Adults with Schizophrenia
inferred← citeshttps://doi.org/10.1017/9781911623861.012openalex-snapshot
Drug Treatment of the Psychoses
inferred← citeshttps://doi.org/10.1017/s0033291719000321openalex-snapshot
The mediating role of depression in pathways linking positive and negative symptoms in schizophrenia. A longitudinal analysis using latent variable structural equation modelling
inferred← citeshttps://doi.org/10.1017/s0033291719002344openalex-snapshot
Depressive psychopathology in first-episode schizophrenia spectrum disorders: a systematic review, meta-analysis and meta-regression
inferred← citeshttps://doi.org/10.1017/s1092852917000554openalex-snapshot
Treating depressive episodes or symptoms in patients with schizophrenia
inferred← citeshttps://doi.org/10.1038/s41380-024-02410-1openalex-snapshot
Psychosis superspectrum II: neurobiology, treatment, and implications
inferred← citeshttps://doi.org/10.1038/s41380-024-02800-5openalex-snapshot
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies
inferred← citeshttps://doi.org/10.1038/s41380-025-03255-yopenalex-snapshot
Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1038/s41380-026-03543-1openalex-snapshot
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trials
inferred← citeshttps://doi.org/10.1038/s41386-026-02467-2openalex-snapshot
Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1038/s41397-021-00234-8openalex-snapshot
Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study
inferred← citeshttps://doi.org/10.1038/s41537-023-00364-xopenalex-snapshot
Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
inferred← citeshttps://doi.org/10.1038/s41572-025-00667-6openalex-snapshot
Schizophrenia
inferred← citeshttps://doi.org/10.1038/s41598-019-44903-yopenalex-snapshot
Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach
inferred← citeshttps://doi.org/10.1038/s41598-025-05024-xopenalex-snapshot
Randomised active controlled trial examining effects of aerobic exercise, cognitive and music interventions on depression, balance and mobility in schizophrenia
inferred← citeshttps://doi.org/10.1042/bsr20193156openalex-snapshot
Clozapine protects adult neural stem cells from ketamine-induced cell death in correlation with decreased apoptosis and autophagy
inferred← citeshttps://doi.org/10.1055/a-0801-2103openalex-snapshot
Pharmakotherapie der therapieresistenten Schizophrenie
inferred← citeshttps://doi.org/10.1055/a-0914-3260openalex-snapshot
Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials
inferred← citeshttps://doi.org/10.1055/s-010-45471openalex-snapshot
inferred← citeshttps://doi.org/10.1080/03007995.2021.1895095openalex-snapshot
Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence
inferred← citeshttps://doi.org/10.1080/08039488.2026.2697960openalex-snapshot
Assessment and treatment of negative symptoms in psychotic disorders – a national clinical guideline
inferred← citeshttps://doi.org/10.1080/14656566.2018.1543409openalex-snapshot
Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment
inferred← citeshttps://doi.org/10.1080/14656566.2020.1717466openalex-snapshot
Pharmacological strategies for the management of comorbid depression and schizophrenia
inferred← citeshttps://doi.org/10.1080/14728214.2020.1773792openalex-snapshot
Emerging 5-HT receptor antagonists for the treatment of Schizophrenia
inferred← citeshttps://doi.org/10.1080/15622975.2018.1557346openalex-snapshot
WFSBP guidelines on how to grade treatment evidence for clinical guideline development
inferred← citeshttps://doi.org/10.1080/17512433.2024.2310715openalex-snapshot
Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis
inferred← citeshttps://doi.org/10.1080/24750573.2019.1699726openalex-snapshot
Adjunct ketamine treatment effects on treatment-resistant depressive symptoms in chronic treatment-resistant schizophrenia patients are short-term and disassociated from regional homogeneity changes in key brain regions – a pilot study
inferred← citeshttps://doi.org/10.1089/cap.2016.29120.bjcopenalex-snapshot
Challenges in the Psychopharmacological Management of Very Early-Onset Schizophrenia and Anxiety
inferred← citeshttps://doi.org/10.1093/brain/awac268openalex-snapshot
Negative symptoms, striatal dopamine and model-free reward decision-making in schizophrenia
inferred← citeshttps://doi.org/10.1093/ijnp/pyaa082openalex-snapshot
Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials
inferred← citeshttps://doi.org/10.1093/ijnp/pyz053openalex-snapshot
Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
inferred← citeshttps://doi.org/10.1093/schbul/sbaa060openalex-snapshot
Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia —Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group
inferred← citeshttps://doi.org/10.1093/schbul/sbaa094openalex-snapshot
The Psychopathology and Neuroanatomical Markers of Depression in Early Psychosis
inferred← citeshttps://doi.org/10.1093/schbul/sbaa153openalex-snapshot
Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1093/schbul/sbaf189openalex-snapshot
Increased Anticholinergic Agent Use With Co-prescription of CYP2D6-Inhibiting SSRIs and Risperidone, but not Aripiprazole: A Nationwide Cohort Study
inferred← citeshttps://doi.org/10.1093/schbul/sbw097openalex-snapshot
Depression and Schizophrenia: Cause, Consequence or Trans-diagnostic Issue?
inferred← citeshttps://doi.org/10.1097/jcp.0000000000000909openalex-snapshot
Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression
inferred← citeshttps://doi.org/10.1097/jcp.0000000000002055openalex-snapshot
Clozapine-Resistant Schizophrenia and Wolff-Parkinson-White Syndrome
inferred← citeshttps://doi.org/10.1097/jcp.0000000000002084openalex-snapshot
Levodopa Augmentation of Antipsychotics for Persistent Negative Symptoms in Schizophrenia
inferred← citeshttps://doi.org/10.1097/nmd.0000000000001004openalex-snapshot
Does Depressive-Type Schizophrenia Exist? How Do We Prove It?
inferred← citeshttps://doi.org/10.1097/yic.0000000000000392openalex-snapshot
Short-term, but not long-term, beneficial effects of concomitant benzodiazepine use on clinical course in patients with schizophrenia
inferred← citeshttps://doi.org/10.1097/yic.0000000000000404openalex-snapshot
Mirtazapine in schizophrenia – an undeservedly overlooked option?
inferred← citeshttps://doi.org/10.1097/yic.0000000000000414openalex-snapshot
Strategies for improving schizophrenia treatment
inferred← citeshttps://doi.org/10.1097/yic.0000000000000465openalex-snapshot
Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report
inferred← citeshttps://doi.org/10.1101/2025.06.20.660782openalex-snapshot
Schizophrenia-associated 22q11.2 deletion elevates striatal acetylcholine and disrupts thalamostriatal projections to produce amotivation in mice
inferred← citeshttps://doi.org/10.1111/acps.12854openalex-snapshot
Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia
inferred← citeshttps://doi.org/10.1111/acps.13020openalex-snapshot
Multi‐trajectories of antidepressant and antipsychotic use: a 11‐year naturalistic study in a community‐based sample
inferred← citeshttps://doi.org/10.1111/eip.12531openalex-snapshot
Predictors of remission during acute treatment of first‐episode schizophrenia patients involuntarily hospitalized and treated with algorithm‐based pharmacotherapy: Secondary analysis of an observational study
inferred← citeshttps://doi.org/10.1111/psyg.12416openalex-snapshot
Concurrent antipsychotic use in older adults treated with antidepressants in Asia
inferred← citeshttps://doi.org/10.1136/bmjment-2023-300771openalex-snapshot
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs
inferred← citeshttps://doi.org/10.1136/eb-2016-102525openalex-snapshot
Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings
inferred← citeshttps://doi.org/10.1159/000511348openalex-snapshot
Psychotic Depression: Diagnosis, Differential Diagnosis, and Treatment
inferred← citeshttps://doi.org/10.1159/000551732openalex-snapshot
Rumination-Focused Cognitive Behavioral Therapy for Negative Symptoms in Early Psychosis: Results of a Pilot Randomized Clinical Trial
inferred← citeshttps://doi.org/10.1176/appi.ajp.2017.16080919openalex-snapshot
Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention
inferred← citeshttps://doi.org/10.1176/appi.ajp.2017.17101126openalex-snapshot
Optimizing the Pharmacologic Treatment of Individuals With First-Episode Psychosis
inferred← citeshttps://doi.org/10.1176/appi.ajp.20250034openalex-snapshot
Effect Size Deflation With Increasing Sample Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action
inferred← citeshttps://doi.org/10.1176/appi.books.9781615373758.bm01openalex-snapshot
Bibliography
inferred← citeshttps://doi.org/10.1176/appi.books.9781615373758.db22bibliographyopenalex-snapshot
Bibliography
inferred← citeshttps://doi.org/10.1176/appi.books.9781615375523.as53openalex-snapshot
Chapter 53. Treatment of Schizophrenia
inferred← citeshttps://doi.org/10.1176/appi.books.9781615379194.lg08openalex-snapshot
Chapter 8. Pharmacological and Somatic Therapies
inferred← citeshttps://doi.org/10.1176/appi.books.9781615379378.lg31openalex-snapshot
Chapter 31. Pharmacotherapy for PTSD
inferred← citeshttps://doi.org/10.1176/appi.books.9798894551289.cd09openalex-snapshot
Chapter 9. Augmentation Strategies for Treatment-Resistant Disorders
inferred← citeshttps://doi.org/10.1176/appi.focus.18310openalex-snapshot
Progress in Schizophrenia Research and Treatment
inferred← citeshttps://doi.org/10.1176/appi.focus.20190047openalex-snapshot
Antipsychotic Polypharmacy
inferred← citeshttps://doi.org/10.1176/appi.ps.201700356openalex-snapshot
Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States
inferred← citeshttps://doi.org/10.1177/00048674251406058openalex-snapshot
Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia
inferred← citeshttps://doi.org/10.1177/00207640241311031openalex-snapshot
Implementation of the modified NAVIGATE program for early schizophrenia in Shanghai through the specialized hospital and community integration: A comparative study
inferred← citeshttps://doi.org/10.1177/0269881118822171openalex-snapshot
Clozapine augmentation strategies – a systematic meta-review of available evidence. Treatment options for clozapine resistance
inferred← citeshttps://doi.org/10.1177/0269881119889296openalex-snapshot
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
inferred← citeshttps://doi.org/10.1177/0269881120909416openalex-snapshot
Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial
inferred← citeshttps://doi.org/10.1177/02698811241278844openalex-snapshot
Clinical effects of CYP2D6 phenoconversion in patients with psychosis
inferred← citeshttps://doi.org/10.1177/0306624x211062139openalex-snapshot
Self-Harm Among Forensic Psychiatric Inpatients With Schizophrenia Spectrum Disorders: An Explorative Analysis
inferred← citeshttps://doi.org/10.1177/07067437241290181openalex-snapshot
Clinical Characteristics of Inpatients with Schizophrenia Spectrum Disorder Treated with Electroconvulsive Therapy: A Population-Level Cross-Sectional Study: Titre: Caractéristiques cliniques des patients hospitalisés présentant un trouble du spectre de la schizophrénie et traités par électrochocs…
inferred← citeshttps://doi.org/10.1177/104012371903100208openalex-snapshot
Effects of a Standardized Extract of Withania Somnifera (Ashwagandha) on Depression and Anxiety Symptoms in Persons with Schizophrenia Participating in a Randomized, Placebo-Controlled Clinical Trial
inferred← citeshttps://doi.org/10.1177/17562848231155022openalex-snapshot
Effect of antidepressants on psychological comorbidities, disease activity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1177/20451253221110014openalex-snapshot
Vortioxetine as adjunctive therapy in the treatment of schizophrenia
inferred← citeshttps://doi.org/10.1186/s12888-024-05777-1openalex-snapshot
Differences in fractional amplitude of low-frequency fluctuations (fALFF) and cognitive function between untreated major depressive disorder and schizophrenia with depressive mood patients
inferred← citeshttps://doi.org/10.1186/s12888-025-07263-8openalex-snapshot
The associations of suicidal ideation with psychopathology and inflammatory cytokines in patients with chronic schizophrenia
inferred← citeshttps://doi.org/10.1186/s12916-017-0960-zopenalex-snapshot
Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance
inferred← citeshttps://doi.org/10.1186/s13063-023-07499-3openalex-snapshot
Antidepressants for the prevention of depression following first-episode psychosis (ADEPP): study protocol for a multi-centre, double-blind, randomised controlled trial
inferred← citeshttps://doi.org/10.1186/s43045-026-00672-9openalex-snapshot
Suicide in schizophrenia: a comprehensive narrative review of risk factors and prevention strategies
inferred← citeshttps://doi.org/10.1192/bjb.2021.15openalex-snapshot
Recognition and management of depression in early psychosis
inferred← citeshttps://doi.org/10.1192/bjp.2018.87openalex-snapshot
Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort
inferred← citeshttps://doi.org/10.1192/bjp.2022.203openalex-snapshot
Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1192/bjp.bp.116.190520openalex-snapshot
Treatment of depression in schizophrenia: Systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1192/bjp.bp.116.195370openalex-snapshot
Schizophrenia — an anxiety disorder?
inferred← citeshttps://doi.org/10.1192/j.eurpsy.2021.13openalex-snapshot
EPA guidance on treatment of negative symptoms in schizophrenia
inferred← citeshttps://doi.org/10.1192/j.eurpsy.2025.10072openalex-snapshot
Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective
inferred← citeshttps://doi.org/10.12788/cp.0049openalex-snapshot
Negative symptoms of schizophrenia: An update
inferred← citeshttps://doi.org/10.12788/cp.0052openalex-snapshot
Impact of the MTHFR C677T genetic variant on depression
inferred← citeshttps://doi.org/10.1371/journal.pone.0243057openalex-snapshot
Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain
inferred← citeshttps://doi.org/10.14288/1.0349186openalex-snapshot
Antipsychotic prescribing patterns on admission to and discharge from a tertiary care program for treatment-resistant psychosis at Riverview Hospital
inferred← citeshttps://doi.org/10.1590/1982-021620171937017openalex-snapshot
Associação entre medicamentos de uso contínuo e tontura em idosos institucionalizados
inferred← citeshttps://doi.org/10.16946/kjsr.2019.22.2.21openalex-snapshot
Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia
inferred← citeshttps://doi.org/10.16946/kjsr.2021.24.1.36openalex-snapshot
Change of Prescribing Pattern after Clozapine Discontinuation: A Retrospective Chart Review
inferred← citeshttps://doi.org/10.17116/jnevro20241240815openalex-snapshot
Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression
inferred← citeshttps://doi.org/10.17650/2712-7672-2020-1-2-29-42openalex-snapshot
Diagnosis and treatment depression in schizophrenia
inferred← citeshttps://doi.org/10.17816/cp172openalex-snapshot
Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression
showing the first 200 of 245
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.